Yuichiro FUJIEDA
(Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Japan)
Olga AMENGUAL
(Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Japan)
Yıl: 2021Cilt: 8Sayı: 2ISSN: 2147-9720 / 2148-4279Sayfa Aralığı: 93 - 99İngilizce

9 0
New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome
Antiphospholipid syndrome (APS) is a systemic disorder clinically characterized by widespread thrombosis and obstetric complications associated with the persistent presence of antiphospholipid antibodies (aPLs). The persistent presence of aPLs represents a thrombotic risk in APS, which can bestratified according to the aPL profile. Thrombosis occurs in both arteries and veins. Notably, arterialthromboses have a higher recurrence compared with venous thromboses and a tendency for recurrence in the same vascular (arterial) site. Secondary prevention of arterial thrombosis requires moreintensive treatment than prevention of venous thrombosis. Data from randomized clinical trials indicated that factor Xa inhibitors should not be recommended for APS. Recurrent thromboses in patientswith APS treated with factor Xa inhibitors were mainly arterial, with a high rate of stroke. Dual antiplatelet therapy may have some benefit for preventing the recurrence of arterial thrombosis in patientswith APS. This review article describes pathogenic mechanisms, clinical features, risk assessment, andmanagement of arterial thrombosis in patients with APS. Particularly, we discuss how secondary prophylaxis may be a useful approach to reduce the occurrence of arterial thrombosis.
DergiDerlemeErişime Açık
  • 1. Amengual O, Atsumi T. Antiphospholipid syndrome, "the best prophet of the future". Modern rheumatology / the Japan Rheumatism Association 2018; 28: 409-16.
  • 2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
  • 3. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/ prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014; 111: 354-64.
  • 4. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: Mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-90.
  • 5. Nakamura H, Oku K, Amengual O, Ohmura K, Fujieda Y, Kato M, et al. First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: A combination of anti-beta2 -glycoprotein I domain I and anti-phosphatidylserine/ prothrombin complex antibodies tests. Arthritis Care Res (Hoboken) 2018; 70: 627-34.
  • 6. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296-304.
  • 7. Fujieda Y, Atsumi T, Amengual O, Odani T, Otomo K, Kato M, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 2012; 21: 1506-14.
  • 8. Kato M, Hisada R, Atsumi T. Clinical profiles and risk assessment in patients with antiphospholipid antibodies. Expert Rev Clin Immunol 2019; 15: 73-81.
  • 9. Mtabaji JP, Moriguchi Y, Nara Y, Mizushima S, Mano M, Yamori Y. Ethnic differences in salt sensitivity: Genetic or environmental factors? Clin Exp Pharmacol Physiol Suppl 1992; 20: 65-7.
  • 10. Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M, Bertero MT, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 2009; 68: 397-9.
  • 11. Gebhart J, Posch F, Koder S, Perkmann T, Quehenberger P, Zoghlami C, et al. Increased mortality in patients with the lupus anticoagulant: The Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood 2015; 125: 3477-83.
  • 12. Vreede AP, Bockenstedt PL, Knight JS. Antiphospholipid syndrome: An update for clinicians and scientists. Curr Opin Rheumatol 2017; 29: 458-66.
  • 13. Wu M, Barnard J, Kundu S, McCrae KR. A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles. J Thromb Haemost 2015; 13: 1928-40.
  • 14. Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68: 1030-5.
  • 15. Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol 2019; 10: 449.
  • 16. Carrera-Marin A, Romay-Penabad Z, Papalardo E, Reyes-Maldonado E, Garcia-Latorre E, Vargas G, et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 2012; 21: 1497-505.
  • 17. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-4.
  • 18. Meroni PL, Macor P, Durigutto P, De Maso L, Gerosa M, Ferraresso M, et al. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood 2016; 127: 365-7.
  • 19. Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135: 239-51.
  • 20. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-5.
  • 21. Wirestam L, Arve S, Linge P, Bengtsson AA. Neutrophils-important communicators in systemic lupus erythematosus and antiphospholipid syndrome. Front Immunol 2019; 10: 2734.
  • 22. Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, Nunez-Alvarez C, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: A newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol 2015; 67: 2990-3003.
  • 23. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-8.
  • 24. Benagiano M, Gerosa M, Romagnoli J, Mahler M, Borghi MO, Grassi A, et al. Beta2 glycoprotein I recognition drives Th1 inflammation in atherosclerotic plaques of patients with primary antiphospholipid syndrome. J Immunol 2017; 198: 2640-8.
  • 25. Rauch J, Salem D, Subang R, Kuwana M, Levine JS. beta2-glycoprotein I-reactive T cells in autoimmune disease. Front Immunol 2018; 9: 2836.
  • 26. Matsuura E, Lopez LR, Shoenfeld Y, Ames PR. beta2-glycoprotein I and oxidative inflammation in early atherogenesis: A progression from innate to adaptive immunity? Autoimmun Rev 2012; 12: 241-9.
  • 27. Matsuura E, Kobayashi K, Hurley BL, Lopez LR. Atherogenic oxidized low-density lipoprotein/ beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2006; 15: 478-83.
  • 28. Otomo K, Amengual O, Fujieda Y, Nakagawa H, Kato M, Oku K, et al. Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-beta2 glycoprotein I antibodies. Lupus 2016; 25: 1288-98.
  • 29. Jiang Y, Arase N, Kohyama M, Hirayasu K, Suenaga T, Jin H, et al. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Int Immunol 2013; 25: 235-46.
  • 30. Tanimura K, Jin H, Suenaga T, Morikami S, Arase N, Kishida K, et al. beta2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood 2015; 125: 2835-44.
  • 31. Fujieda Y, Amengual O, Atsumi T. Pathogenic role of antiphospholipid antibodies: An update. Lupus 2018; 27: 2012-3.
  • 32. Hisada R, Kato M, Sugawara E, Kanda M, Fujieda Y, Oku K, et al. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. J Thromb Haemost 2019; 17: 1134-43.
  • 33. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
  • 34. Bertero MT, Bazzan M, Carignola R, Montaruli B, Silvestro E, Sciascia S, et al. Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): Demographic features, risk factors, clinical and laboratory profile. Lupus 2012; 21: 806-9.
  • 35. Duarte-Garcia A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, et al. The epidemiology of antiphospholipid syndrome: A population-based study. Arthritis Rheum 2019; 71: 1545-52.
  • 36. Hwang JJ, Shin SH, Kim YJ, Oh YM, Lee SD, Kim YH, et al. Epidemiology of antiphospholipid syndrome in Korea: A nationwide population-based study. J Korean Med Sci 2020; 35: e35.
  • 37. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: A prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083- 6.
  • 38. Gaspersic N, Zaletel M, Kobal J, Zigon P, Cucnik S, Semrl SS, et al. Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event. Clin Rheumatol 2019; 38: 379-84.
  • 39. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65: 1869-73.
  • 40. Loczi L, Kappelmayer J, Tarr T, Bagoly Z. Antiphospholipid syndrome and the risk of myocardial infarction: Current evidence and uncertainties. Kardiol Pol 2020; 78: 6-14.
  • 41. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-52.
  • 42. Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study. Lupus 2014; 23: 1468-76.
  • 43. Yelnik CM, Urbanski G, Drumez E, Sobanski V, Maillard H, Lanteri A, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus 2017; 26: 163-9.
  • 44. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012; 64: 504-12.
  • 45. Hisada R, Kato M, Sugawara E, Fujieda Y, Oku K, Bohgaki T, et al. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: A longitudinal study. J Thromb Haemost 2017; 15: 1782-7.
  • 46. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: The global anti-phospholipid syndrome score. Rheumatology 2013; 52: 1397-403.
  • 47. Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum 2019; 49: 464-8.
  • 48. Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. Autoimmun Rev 2014; 13: 281-91.
  • 49. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16: 39-45.
  • 50. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29-36.
  • 51. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1998; 29: 2245-53.
  • 52. Wang CR, Liu MF. Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: A single-center experience. Semin Arthritis Rheum 2016; 46: 102-8.
  • 53. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
  • 54. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
  • 55. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
  • 56. Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3: e426-36.
  • 57. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-71.
  • 58. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomo A, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med 2019; 171: 685-94.
  • 59. Sato T, Nakamura H, Fujieda Y, Ohnishi N, Abe N, Kono M, et al. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: A longitudinal cohort study. Lupus 2019; 28: 1577-82.
  • 60. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
  • 61. Ohnishi N, Fujieda Y, Hisada R, Nakamura H, Kato M, Oku K, et al. Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology 2019; 58: 969-74.
  • 62. Cassia MA, Alberici F. Prevention of arterial thrombosis recurrence in anti-phospholipid syndrome: Are anti-platelets the answer? Rheumatology 2019; 58: 935-6.
  • 63. Nuri E, Taraborelli M, Andreoli L, Tonello M, Gerosa M, Calligaro A, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res 2017; 65: 17-24.
  • 64. van den Hoogen LL, Fritsch-Stork RD, Versnel MA, Derksen RH, van Roon JA, Radstake TR. Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Ann Rheum Dis 2016; 75: e81.
  • 65. Watanabe T, Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2018; 27: 225-34.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.